Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.
DeNardo
G L
GL
Department of Internal Medicine, University of California, Davis Medical Center, Sacramento 95817.
DeNardo
S J
SJ
O'Grady
L F
LF
Levy
N B
NB
Adams
G P
GP
Mills
S L
SL
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D015448:Leukemia, B-Cell / Q000532:radiotherapy*; D008223:Lymphoma / Q000532:radiotherapy*; D008657:Metabolic Clearance Rate
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes